Neurovascular dysfunction, inflammation and endothelial activation: Implications for the pathogenesis of Alzheimer's disease

Journal of Neuroinflammation

Volumn 8, Issue , 2011, Pages

  Grammas, Paula ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PROTEIN;

ALZHEIMER DISEASE; CARDIOVASCULAR RISK; CELL ACTIVATION; CELL FUNCTION; CHRONIC INFLAMMATION; ENCEPHALITIS; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; FUNCTIONAL MORPHOLOGY; HUMAN; INFLAMMATORY DISEASE; NEOVASCULARIZATION (PATHOLOGY); NERVE CELL LESION; NEUROPATHOLOGY; NONHUMAN; PROTEIN TRANSPORT; REVIEW; BRAIN; BRAIN CIRCULATION; CARDIOVASCULAR DISEASE; DISEASE COURSE; INFLAMMATION; PATHOLOGY; PATHOPHYSIOLOGY; RISK FACTOR; VASCULAR ENDOTHELIUM;

ALZHEIMER DISEASE; BRAIN; CARDIOVASCULAR DISEASES; CEREBROVASCULAR CIRCULATION; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; RISK FACTORS;

EID: 79953075804     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-8-26     Document Type: Review

References (184)

1. Alzheimer's Association website., http://www.alz.org
2. Formichi P, Parnetti L, Radi E, Cevenini G, Dotti MT, Federico A. CSF biomarkers profile in CADASIL-A model of pure vascular dementia: Usefulness in differential diagnosis in the dementia disorder. Int J Alzheimers Dis 2010, 2010. 959257, 2933894, 20827312.
3. Sparks DL, Hunsaker JC, Scheff SW, Kryscio RJ, Henson JL, Markesbery WR. Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease. Neurobiol Aging 1990, 11:601-607. 10.1016/0197-4580(90)90024-T, 1704106.
4. Sparks DL, Liu J, Scheff SW, Coyne CM, Hunsker JC. Temporal sequence of plaque formation in the cerebral cortex of non-demented individuals. J Neuropathol Exp Neurol 1993, 52:135-142. 10.1097/00005072-199303000-00006, 8440995.
5. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993, 90:1977-1981. 10.1073/pnas.90.5.1977, 46003, 8446617.
6. Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, van Harskamp F, van Duijn CN, Van Broeckhoven C, Grobbee DE. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997, 349:151-154. 10.1016/S0140-6736(96)09328-2, 9111537.
7. Miller JW. Homocysteine and Alzheimer's disease. Nutr Rev 1999, 57:126-129.
8. Stewart R, Prince M, Mann A. Vascular risk factors and Alzheimer's disease. Aust N Z J Psychiatry 1999, 33:809-813. 10.1046/j.1440-1614.1999.00657.x, 10619206.
9. Schmidt R, Schmidt H, Fazekas F. Vascular risk factors in dementia. J Neurol 2000, 247:81-87. 10.1007/s004150050021, 10751108.
10. Shi J, Perry G, Smith MA, Friedland RP. Vascular abnormalities: the insidious pathogenesis of Alzheimer's disease. Neurobiol Aging 2000, 21:357-361. 10.1016/S0197-4580(00)00119-6, 10867221.
11. Sparks DL, Martin TA, Gross DR, Hunsaker JC. Link between heart disease, cholesterol, and Alzheimer's disease: a review. Microsc Res Tech 2000, 50:287-290. 10.1002/1097-0029(20000815)50:4<287::AID-JEMT7>3.0.CO;2-L, 10936882.
12. Marx J. Alzheimer's disease. Bad for the heart, bad for the mind?. Science 2001, 294:508-509. 10.1126/science.294.5542.508, 11641483.
13. Rhodin JA, Thomas T. A vascular connection to Alzheimer's disease. Microcirculation 2001, 8:207-220.
14. de la Torre JC. Alzheimer disease as a vascular disorder: nosological evidence. Stroke 2002, 3:1152-1162.
15. Pansari K, Gupta A, Thomas P. Alzheimer's disease and vascular factors: facts and theories. Int J Clin Pract 2002, 56:197-203.
16. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PW, Wolff PA. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002, 346:476-483. 10.1056/NEJMoa011613, 11844848.
17. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 2004, 5:347-360. 10.1038/nrn1387, 15100718.
18. Ruitenberg A, den Heijer T, Bakker SL, van Swieten JC, Koudstaal PJ, Hofman A, Breteler MM. Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study. Ann Neurol 2005, 57:789-794. 10.1002/ana.20493, 15929050.
19. Zlokovic BV. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci 2005, 28:202-208. 10.1016/j.tins.2005.02.001, 15808355.
20. de la Torre JC. How do heart disease and stroke become risk factors for Alzheimer's disease?. Neurol Res 2006, 28:637-644. 10.1179/016164106X130362, 16945216.
21. Stampfer MJ. Cardiovascular disease and Alzheimer's disease: common links. J Intern Med 2006, 260:211-223. 10.1111/j.1365-2796.2006.01687.x, 16918818.
22. Beach TG, Wilson JR, Sue LI, Newell A, Poston M, Cisneros R, Pandya Y, Esh C, Connor DJ, Sabbagh M, Walker DG, Roher AE. Circle of Willis atherosclerosis: association with Alzheimer's disease, neuritic plaques and neurofibrillary tangles. Acta Neuropathol 2007, 113:1-21.
23. Lanari A, Silvestrelli G, De Dominicis P, Tomassoni D, Amenta F, Parnetti L. Arterial hypertension and cognitive dysfunction in physiologic and pathologic aging of the brain. Am J Geriatr Cardiol 2007, 16:158-164. 10.1111/j.1076-7460.2007.06502.x, 17483667.
24. Luchsinger JA, Reitz C, Patel B, Tang MX, Manly JJ, Mayeux R. Relation of diabetes to mild cognitive impairment. Arch Neurol 2007, 64:570-575. 10.1001/archneur.64.4.570, 17420320.
25. Van Oijen M, de Jong FJ, Witteman JC, Hofman A, Koudstaal PJ, Breteler MM. Atherosclerosis and risk for dementia. Ann Neurol 2007, 61:403-410. 10.1002/ana.21073, 17328068.
26. Helzner EP, Luchsinger JA, Scarmeas N, Cosentino S, Brickman AM, Glymour MM, Stern Y. Contribution of vascular risk factors to the progression in Alzheimer's disease. Arch Neurol 2009, 66:343-348. 10.1001/archneur.66.3.343, 19273753.
27. Altman R, Rutledge JC. The vascular contribution to Alzheimer's disease. Clin Sci (Lond) 2010, 119:407-421. 10.1042/CS20100094, 2950620, 20684749.
28. de la Torre JC. The vascular hypothesis of Alzheimer's disease: bench to bedside and beyond. Neurodegener Dis 2010, 7:116-121. 10.1159/000285520, 20173340.
29. Iadecola C. The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol 2010, 120:287-296. 10.1007/s00401-010-0718-6, 20623294.
30. Kalaria RN. Vascular basis for brain degeneration: faltering controls and risk factors for dementia. Nutr Rev 2010, 68:S74-S87. 10.1111/j.1753-4887.2010.00352.x, 21091952.
31. Knopman DS, Roberts R. Vascular risk factors: Imaging and neuropathologic correlates. J Alzheimer Dis 2010, 20:699-709.
32. Zlokovic BV, Deane R, Sagare AP, Bell RD, Winkler EA. Low-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer's amyloid β-peptide elimination from the brain. J Neurochem 2010, 115:1077-1089. 10.1111/j.1471-4159.2010.07002.x, 2972355, 20854368.
33. Grammas P. A damaged microcirculation contributes to neuronal cell death in Alzheimer's disease. Neurobiol Aging 2000, 21:199-205. 10.1016/S0197-4580(00)00102-0, 10867204.
34. Zuliani G, Cavalieri M, Galvani M, Passaro A, Munari MR, Bosi C, Zurlo A, Fellin R. Markers of endothelial dysfunction in older subjects with late onset Alzheimer's disease or vascular dementia. J Neurol Sci 2008, 272:164-170. 10.1016/j.jns.2008.05.020, 18597785.
35. de la Torre JC. Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol 2004, 3:184-190. 10.1016/S1474-4422(04)00683-0, 14980533.
36. Bell RD, Zlokovic BV. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol 2009, 118:103-113. 10.1007/s00401-009-0522-3, 19319544.
37. Pakrasi S, O'Brien JT. Emission tomography in dementia. Nucl Med Commun 2005, 26:189-196. 10.1097/00006231-200503000-00003, 15722899.
38. Jagust WJ, Bandy D, Chen K, Foster NL, Landau SM, Mathis CA, Price JC, Reiman EM, Skovronsky D, Koeppe RA, . Alzheimer's Disease Neuroimaging Initiative The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement 2010, 6:221-229. 10.1016/j.jalz.2010.03.003, 20451870, Alzheimer's Disease Neuroimaging Initiative.
39. Scheibel AB. Changes in brain capillary structure in aging and dementia. 1984, 137-149. Alan R. Liss, Inc., New York, J Wertheimer and M Marois, in Senile Dementia Outlook for the Future.
40. Miyakawa T, Shimoji A, Kumamoto R, Higuchi T. The relationship between senile plaques and cerebral blood vessels in Alzheimer's disease and senile dementia. Morphological mechanism of senile plaque production. Virchows Arch (Cell Pathol) 1982, 40:121-129.
41. Davies DC, Hardy JA. Blood-brain barrier in aging and Alzheimer's disease. Neurobiol Aging 1988, 9:46-48. 10.1016/S0197-4580(88)80017-4, 3380253.
42. Masters CL, Beyreuther K. The blood-brain barrier in Alzheimer's disease and normal aging. Neurobiol Aging 1988, 9:43-44. 10.1016/S0197-4580(88)80015-0, 3380251.
43. Araki K, Miyakawa T, Katsuragi S. Ultrastructure of senile plaque using thick sections in the brain with Alzheimer's disease. Jpn J Psychiatry Neurol 1991, 45:85-89.
44. de la Torre JC, Mussivand T. Can a disturbed brain microcirculation cause Alzheimer's disease?. Neurol Res 1993, 15:146-153.
45. Buee L, Hof PR, Bouras C, Delacourte A, Perl DP, Morrison JH, Fillit HM. Pathological alterations of the cerebral microvasculature in Alzheimer's disease and related dementing disorders. Acta Neuropathol 1994, 87:469-480. 10.1007/BF00294173, 8059599.
46. Dorheim MA, Tracey WR, Pollock JS, Grammas P. Nitric oxide is elevated in Alzheimer's brain microvessels. Biochem Biophys Res Comm 1994, 205:659-665. 10.1006/bbrc.1994.2716, 7528015.
47. Kalaria RN, Hedera P. Differential degeneration of the cerebral microvasculature in Alzheimer's disease. NeuroReport 1995, 6:477-480. 10.1097/00001756-199502000-00018, 7766847.
48. Kalaria RN, Pax AB. Increased collagen content of cerebral microvessels in Alzheimer's disease. Brain Res 1995, 705:349-352. 10.1016/0006-8993(95)01250-8, 8821769.
49. Kalaria RN. Cerebral vessels in aging and Alzheimer's disease. Pharmacol Ther 1996, 72:193-214. 10.1016/S0163-7258(96)00116-7, 9364575.
50. Claudio L. Ultrastructural features of the blood-brain barrier in biopsy tissue from Alzheimer's disease patients. Acta Neuropathol 1996, 91:6-14. 10.1007/s004010050386, 8773140.
51. de la Torre JC. Cerebromicrovascular pathology in Alzheimer's disease compared to normal aging. Gerontology 1997, 43:26-43. 10.1159/000213834, 8996828.
52. Grammas P, Moore P, Weigel PH. Microvessels from Alzheimer's disease brain kill neurons in vitro. Am J Pathol 1999, 154:337-342. 10.1016/S0002-9440(10)65280-7, 1850001, 10027392.
53. Farkas E, Luiten PG. Cerebral microvascular pathology in aging and Alzheimer's disease. Prog Neurobiol 2001, 64:575-611. 10.1016/S0301-0082(00)00068-X, 11311463.
54. Grammas P, Ovase R. Inflammatory factors are elevated in brain microvessels in Alzheimer's disease. Neurobiol Aging 2001, 22:837-842. 10.1016/S0197-4580(01)00276-7, 11754990.
55. Grammas P, Ovase R. Cerebrovascular TGF-β contributes to inflammation in the Alzheimer's brain. Am J Pathol 2002, 160:1583-1587. 10.1016/S0002-9440(10)61105-4, 1850858, 12000710.
56. Christov A, Ottman T, Hamdheydari L, Grammas P. Structural changes in Alzheimer's disease brain microvessels. Current Alz Res 2008, 5:392-395.
57. Meyer EP, Ulmann-Schuler A, Staufenbiel M, Krucker T. Altered morphology and 3D architecture of brain vasculature in a mouse model for Alzheimer's disease. Proc Natl Acad Sci USA 2008, 105:3587-3592. 10.1073/pnas.0709788105, 2265182, 18305170.
58. Duong T, Nikolaeva M, Acton PJ. C-reactive protein-like immunoreactivity in the neurofibrillary tangles of Alzheimer's disease. Brain Res 1997, 749:152-156. 10.1016/S0006-8993(96)01359-5, 9070642.
59. Cleland SJ, Sattar N, Petrie JR, Forouhi NG, Elliott HL, Connell JM. Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Sci 2000, 988:531-535.
60. Fay WP. Linking inflammation and thrombosis: Role of C-reactive protein. World J Cardiol 2010, 2:365-369. 10.4330/wjc.v2.i11.365, 3006472, 21179303.
61. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999, 340:115-126. 10.1056/NEJM199901143400207, 9887164.
62. De Caterina R, Massaro M, Scoditti E, Annunziata Carluccio M. Pharmacological modulation of vascular inflammation in atherothrombosis. Ann NY Acad Sci 2010, 1207:23-31. 10.1111/j.1749-6632.2010.05784.x, 20955422.
63. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell 2010, 140:918-934. 10.1016/j.cell.2010.02.016, 2873093, 20303880.
64. Cooper NR, Bradt BM, O'Barr S, Yu JX. Focal inflammation in the brain: role in Alzheimer's disease. Immunol Res 2000, 21:159-165. 10.1385/IR:21:2-3:159, 10852113.
65. Neuroinflammation Working Group Inflammation and Alzheimer's disease. Neurobiol Aging 2000, 21:383-421. 10.1016/S0197-4580(00)00124-X, 10858586, Neuroinflammation Working Group.
66. Tarkowski E. Cytokines in dementia. Curr Drug Targets Inflamm Allergy 2002, 1:193-200. 10.2174/1568010023344670, 14561200.
67. McGeer EG, McGeer PL. Inflammatory processes in Alzheimer's disease. Prog Neuropsycholpharmacol Biol Psychiatry 2003, 27:741-749.
68. McGeer PL, McGeer EG. Inflammation and the degenerative diseases of aging. Ann NY Acad Sci 2004, 1035:104-116. 10.1196/annals.1332.007, 15681803.
69. Ho GJ, Drego R, Hakimian E, Masliah E. Mechanisms of cell signaling and inflammation in Alzheimer's disease. Curr Drug Targets Inflamm Allergy 2005, 4:247-256. 10.2174/1568010053586237, 15853747.
70. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response?. Nat Med 2006, 12:1005-1015.
71. Lee YJ, Han SB, Nam SY, Oh KW, Hong JT. Inflammation and Alzheimer's disease. Arch Pharm Res 2010, 33:1539-155. 10.1007/s12272-010-1006-7, 21052932.
72. Lee DC, Rizer J, Selenica M-LB, Reid P, Kraft C, Johnson A, Blair L, Gordon MN, Dickey CA, Morgan D. LPS-induced inflammation exacerbates phospho-tau pathology in rTg4510 mice. J Neuroinflammation 2010, 7:56. 10.1186/1742-2094-7-56, 2949628, 20846376.
73. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 1996, 47:425-432.
74. Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997, 48:626-632.
75. Hayden KM, Zandi PP, Khachaturian AS, Szekely CA, Fotuhi M, Norton MC, Tschanz JT, Pieper CF, Corcoran C, Lyketsos CG, Breitner JC, Welsh-Bohmer KA, . Cache County Investigators Does NSAID use modify cognitive trajectories in the elderly? The Cache County study. Neurology 2007, 69:275-282. 10.1212/01.wnl.0000265223.25679.2a, 17636065, Cache County Investigators.
76. Vlad SC, Miller DR, Kowall NW, Feson DT. Protective effects of NSAIDs on the development of Alzheimer's disease. Neurology 2008, 70:1672-1677. 10.1212/01.wnl.0000311269.57716.63, 2758242, 18458226.
77. Pasinetti GML. From epidemiology to therapeutic trials with anti-inflammatory drugs in Alzheimer's disease: the role of NSAIDs and cyclooxygenase in beta-amyloidosis and clinical dementia. J Alzheimers Dis 2002, 4:435-445.
78. Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, Tran T, Ubeda O, Ashe KH, Frautschy SA, Cole GM. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 2000, 20:5709-5714.
79. Lim GP, Yang F, Chu T, Gahtan E, Ubeda O, Beech W, Overmier JB, Hsiao-Ashec K, Frautschy SA, Cole GM. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol Aging 2001, 22:983-991. 10.1016/S0197-4580(01)00299-8, 11755007.
80. Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ 2003, 327:128. 10.1136/bmj.327.7407.128, 165707, 12869452.
81. Yan Q, Zhang J, Liu H, Babu-Khan S, Vassar R, Biere AL, Citron M, Landreth G. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci 2003, 23:7504-7509.
82. Kotilinek LA, Westerman MA, Wang Q, Panizzon K, Lim GP, Simonyi A, Lesne S, Falinska A, Younkin LH, Younkin SG, Rowan M, Cleary J, Wallis RA, Sun GY, Cole G, Frautschy S, Anwyl R, Ashe KH. Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity. Brain 2008, 131:651-664. 10.1093/brain/awn008, 2628581, 18292081.
83. Szekely CA, Thorne JE, Zandi PP, Ek M, Messias E, Breitner JC, Goodman SN. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 2004, 23:159-169. 10.1159/000078501, 15279021.
84. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ, . Alzheimer's Disease Cooperative Study Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized clinical trial. JAMA 2003, 289:2819-2826. 10.1001/jama.289.21.2819, 12783912, Alzheimer's Disease Cooperative Study.
85. Green RD, Schneider LS, Hendrix SB, Zavitz KH, Swabb E. Safety and efficacy of tarenflurbil in subjects with mild Alzheimer's disease: results from an 18-month multi-center phase 3 trial. Alzheimers Dement 2008, 4(Suppl):T165.
86. Martin BK, Szekely C, Brandt J, Piantadosi S, Breitner JC, Craft S, Evans D, Green R, Mullan M. ADAPT Research Group Cognitive function over time in the Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 2008, 896-905. 2925195, 18474729, ADAPT Research Group.
87. Zandi PP, Anthony JC, Hayden KM, Mehta K, Mayer L, Breitner JC, . Cache County Study Investigators Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology 2002, 59:880-886. Cache County Study Investigators.
88. Varvel NH, Bhasker K, Kounnas MZ, Wagner SL, Yang Y, Lamb BT, Herrup K. NSAIDS prevent, but do not reverse, neuronal cell cycle reentry in a mouse model of Alzheimer disease. J Clin Invest 2009, 119:3692-3701. 10.1172/JCI39716, 2786797, 19907078.
89. Tehranian R, Hasanvan H, Iverfeldt K, Post C, Schultzberg M. Early induction of interleukin-6 mRNA in the hippocampus and cortex of APPsw transgenic mice Tg2576. Neurosci Lett 2001, 301:54-58. 10.1016/S0304-3940(01)01592-0, 11239715.
90. Janelsins MC, Mastrangelo MA, Oddo S, LaFerla FM, Federoff HJ, Bowers WJ. Early correlation of microglial activationwith enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice. J Neuroinflammation 2005, 2:23. 10.1186/1742-2094-2-23, 1276812, 16232318.
91. Frohman EM, Frohman TC, Gupta S, de Fourgerolles A, van den Noort S. Expression of intercellular adhesion molecule 1 (ICAM-1) in Alzheimer's disease. J Neuro Sci 1991, 106:105-111.
92. Pereira HA, Kumar P, Grammas P. Expression of CAP37, a novel inflammatory mediator, in Alzheimer's disease. Neurobiol Aging 1996, 17:753-759. 10.1016/S0197-4580(96)00118-2, 8892348.
93. Thirumangalakudi L, Samany PG, Owoso A, Wiskar B, Grammas P. Angiogenic proteins are expressed by brain blood vessels in Alzheimer's disease. J Alzheimers Dis 2006, 10:111-118.
94. Li M, Shang DS, Zhao WD, Tian L, Li B, Fang WG, Zhu L, Man SM, Chen YH. Amyloid beta interaction with receptor for advanced glycation end products up-regulates brain endothelial CCR5 expression and promotes T cells crossing the blood-brain barrier. J Immunol 2009, 182:5778-5788. 10.4049/jimmunol.0803013, 19380826.
95. Deane R, Yan SD, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione F, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B. RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003, 9:907-913. 10.1038/nm890, 12808450.
96. Vukic V, Callaghan D, Walker D, Lue LF, Liu QY, Couraud PO, Romero IA, Weksler B, Stanimirovic DB, Zhang W. Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in Alzheimer's brain is mediated by the JNK-AP1 signaling pathway. Neurobiol Dis 2009, 34:95-106. 10.1016/j.nbd.2008.12.007, 2720310, 19162185.
97. Paris D, Townsend KP, Obregon DF, Humphrey J, Mullan M. Pro-inflammatory effort of freshly solubilized beta-amyloid peptides in the brain. Prostaglandins Other Lipid Mediat 2002, 70:1-12. 10.1016/S0090-6980(02)00111-9, 12428674.
98. Suo Z, Tan J, Placzek A, Crawford F, Fang C, Mullan M. Alzheimer's beta-amyloid peptides induce inflammatory cascade in human vascular cells: the roles of cytokines and CD40. Brain Res 1998, 807:110-117. 10.1016/S0006-8993(98)00780-X, 9757011.
99. Poveshchenko AF, Konenkov VI. Mechanisms and factors of angiogenesis. Usp Fiziol Nauk 2010, 41:68-89.
100. Sgambato A, Cittadini A. Inflammation and cancer: a multifaceted link. Eur Rev Med Pharmacol Sci 2010, 14:263-268.
101. Pogue AI, Lukiw WJ. Angiogenic signaling in Alzheimer's disease. Neuroreport 2004, 15:1507-1510. 10.1097/01.wnr.0000130539.39937.1d, 15194884.
102. Miklossy J. Cerebral hypoperfusion induces cortical watershed microinfarcts which may further aggravate cognitive decline in Alzheimer's disease. Neurol Res 2003, 25:605-610. 10.1179/016164103101202048, 14503014.
103. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003, 9:677-684. 10.1038/nm0603-677, 12778166.
104. Yamakawa M, Liu LX, Date T, Belanger AJ, Vincent KA, Akita GY, Kuriyama T, Cheng SH. Hypoxia-inducible factor-1 mediates activation of cultured vascular endothelial cells by inducing multiple angiogenic factors. Circ Res 2003, 93:664-673. 10.1161/01.RES.0000093984.48643.D7, 12958144.
105. Kalaria RN, Cohen DL, Premkumar DR, Nag S, LaManna JC, Lust WD. Vascular endothelial growth factor in Alzheimer's disease and experimental ischemia. Brain Res Mol Brain Res 1998, 62:101-105. 10.1016/S0169-328X(98)00190-9, 9795165.
106. Tarkowski E, Issa R, Sjogren M, Wallin A, Blennow K, Tarkowski A, Kumar P. Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia. Neurobiol Aging 2002, 23:237-243. 10.1016/S0197-4580(01)00285-8, 11804709.
107. Del Bo R, Ghezzi S, Scarpini E, Bresolin N, Comi GP. VEGF genetic variability is associated with increased risk of developing Alzheimer's disease. J Neurol Sci 2009, 283:66-68. 10.1016/j.jns.2009.02.318, 19272614.
108. Grammas P, Ghatreh-Samany P, Thirmangalakudi L. Thrombin and Inflammatory proteins are elevated in Alzheimer's disease microvessels: Implications for disease pathogenesis. J Alzheimer Dis 2006, 9:51-58.
109. Yin X, Wright J, Wall T, Grammas P. Brain endothelial cells synthesize neurotoxic thrombin in Alzheimer's disease. Am J Pathol 2010, 176:1600-1606. 10.2353/ajpath.2010.090406, 20150433.
110. Lukiw WJ, Ottlecz A, Lambrou G, Grueninger M, Finely J, Thompson HW, Bazan NG. Coordinate activation of HIF-1 and NF-kappaB DNA binding and COX-2 and VEGF expression in retinal cells by hypoxia. Invest Ophthalmol Vis Sci 2003, 44:4163-4170. 10.1167/iovs.02-0655, 14507857.
111. Jellinger KA. Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm 2002, 109:813-836. 10.1007/s007020200068, 12111471.
112. Buee L, Hof PR, Delacourte A. Brain microvascular changes in Alzheimer's disease and other dementias. Ann NY Acad Sci 1997, 826:7-24. 10.1111/j.1749-6632.1997.tb48457.x, 9329677.
113. Edelber JM, Reed MJ. Aging and angiogenesis. Front Biosci 2003, 8:s1199-s1209. 10.2741/1166, 12957863.
114. Paris D, Townsend K, Quadros A, Humphrey J, Sun J, Brem S, Wotoczek-Obadia M, DelleDonne A, Patel N, Obregon DF, Crescentini R, Abdullah L, Coppola D, Rojiani AM, Crawford F, Sebti SM, Mullan M. Inhibition of angiogenesis by Aβ peptides. Angiogenesis 2004, 7:75-85. 10.1023/B:AGEN.0000037335.17717.bf, 15302999.
115. Paris D, Patel N, DelleDonne A, Quadros A, Smeed R, Mullan M. Impaired angiogenesis in a transgenic mouse model of cerebral amyloidosis. Neurosci Lett 2004, 366:80-85. 10.1016/j.neulet.2004.05.017, 15265595.
116. Paris D, Ait-Ghezala G, Mathura VS, Patel N, Quadros A. Anti-angiogenic activity of the mutant Dutch Aβ peptide on human brain microvascular endothelial cells. Mol Brain Res 2005, 136:212-230. 10.1016/j.molbrainres.2005.02.011, 15893605.
117. Monro OR, Mackic JB, Yamada S, Segal MB, Ghiso J, Maurer C, Calero M, Frangione B, Zlokovic BV. Substitution at codon 22 reduces clearance of Alzheimer's amyloid-beta peptide from the cerebrospinal fluid and prevents its transport from the central nervous system into blood. Neurobiol Aging 2002, 23:405-412.
118. Grammas P, Botchlet T, Fugate R, Ball MJ, Roher AE. Alzheimer disease amyloid proteins inhibit brain endothelial cell proliferation in vitro. Dementia 1995, 6:126-130.
119. Wu Z, Guo H, Chow N, Sallstrom J, Bell RD, Deane R, Brooks AI, Kanagala S, Rubio A, Sagare A, Liu D, Li F, Armstrong D, Gasiewicz T, Zidovetzki R, Song X, Hofman F, Zlokovic BV. Role of the MEOX2 gene in neurovascular dysfunction in Alzheimer disease. Nat Med 2005, 11:959-965.
120. Felmeden DC, Blann AD, Lip GYH. Angiogenesis: basic pathophysiology and implications for disease. Eur Heart J 2003, 24:585-603.
121. Milkiewicz M, Ispanovic E, Doyle JL, Haas TL. Regulators of angiogenesis and strategies for their therapeutic manipulation. Int J Biochem Cell Biol 2006, 38:333-357. 10.1016/j.biocel.2005.10.006, 16309946.
122. Breitner JC, Welsh KA, Helms MJ, Gaskell PC, Gau BA, Roses AD, Pericak-Vance MA, Saunders AM. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging 1995, 16:523-530. 10.1016/0197-4580(95)00049-K, 8544901.
123. Forette F, Seux ML, Staessen JA, Thijs L, Birkenhager WH, Babarskiene MR, Babeanu S, Bossini A, Gil-Extremera B, Girerd X, Laks T, Lilov E, Moisseyev V, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Fagard R. Prevention of dementia in randomized double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998, 352:1347-1351. 10.1016/S0140-6736(98)03086-4, 9802273.
124. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer's disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000, 57:1439-1443. 10.1001/archneur.57.10.1439, 11030795.
125. Vagnucci AD, Li WW. Alzheimer's disease and angiogenesis. Lancet 2003, 361:605-608. 10.1016/S0140-6736(03)12521-4, 12598159.
126. Lema MJ. Emerging options with coxib therapy. Cleve Clin J Med 2002, 69(Suppl 1):S176-S184.
127. Martel-Pelletier J, Pelletier JP, Fahmi H. Cyclooxygenase-2 and prostaglandins in articular tissues. Semin Arthritis Rheum 2003, 33:155-167. 40, 10.1016/S0049-0172(03)00134-3, 14671726.
128. De Filippis D, Cipriano M, Esposito G, Scuderi C, Steardo L, Iuvone T. Are anti-angiogenic drugs useful in neurodegenerative disorders?. CNS & Neurological Disorders - Drug Targets 2010, 9:807-812.
129. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ, Tarnawski SS. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999, 5:1418-1423. 10.1038/70995, 10581086.
130. Tarnawski AS, Jones MK. Inhibition of angiogenesis by NSAIDs: molecular mechanisms and clinical implications. J Mol Med 2003, 81:627-636. 10.1007/s00109-003-0479-y, 13679997.
131. Boonmasawai S, Akarasereenont P, Techatraisak K, Thaworn A, Chotewuttakorn S, Palo T. Effects of selective COX inhibitors and classical NSAIDs on endothelial cell proliferation and migration induced by human cholangiocarcinoma cell culture. J Med Assoc Thai 2009, 92:1508-1515.
132. Alkam T, Nitta A, Mizoguchi H, Saito K, Seshima M, Itoh A, Yamada K, Nabeshima T. Restraining tumor necrosis factor-alpha by thalidomide prevents the amyloid beta-induced impairment of recognition and memory in mice. Beh Brain Res 2008, 189:100-106.
133. Ryu JK, McLarnon JG. Thalidomide inhibition of perturbed vasculature and glial-derived tumor necrosis factor-alpha in an animal model of inflamed Alzheimer's disease brain. Neurobiol Dis 2008, 29:254-266. 10.1016/j.nbd.2007.08.019, 17964176.
134. Araυjo FA, Rocha MA, Mendes JB, Andrade SP. Atorvastatin inhibits inflammatory angiogenesis in mice through down regulation of VEGF, TNF-alpha and TGF-beta1. Biomed Pharmacother 2010, 64:29-34.
135. Hata Y, Miura M, Asato R, Kita T, Oba K, Kawahara S, Arita R, Kohno R, Nakao S, Ishibashi T. Antiangiogenic mechanisms of simvastatin in retinal endothelial cells. Graefes Arch Clin Exp Ophthalmol 2010, 248:667-673. 10.1007/s00417-009-1282-4, 20155363.
136. Wang Q, Yan J, Chen X, Li J, Yang Y, Weng J, Deng C, Yenari MA. Statins: multiple neuroprotective mechanisms in neurodegenerative diseases. Exp Neurol 2010,
137. Gimbrone MA. Vascular endothelium, hemodynamic forces and atherogenesis. Am J Pathol 1999, 155:1-5. 10.1016/S0002-9440(10)65090-0, 1866678, 10393828.
138. Libby P, Ridker PM, Hansson GK, . Leducq Transatlantic Network on Atherothrombosis Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009, 54:2129-2138. 10.1016/j.jacc.2009.09.009, 2834169, 19942084, Leducq Transatlantic Network on Atherothrombosis.
139. Gimbrone MA. Endothelial dysfunction, biomechanical forces and the pathobiology of atherosclerosis. Trans Am Clin Climatol Assoc 2010, 121:115-127. 2917138, 20697555.
140. Bauersachs J, Widder JD. Endothelial dysfunction in heart failure. Pharm Reports 2008, 60:119-126.
141. Pober JS, Min W, Bradley JR. Mechanisms of endothelial dysfunction, injury and death. Annu Rev Pathol 2009, 4:71-95. 10.1146/annurev.pathol.4.110807.092155, 18754744.
142. Andjelkovic AV, Pachter JS. Central nervous system endothelium in neuroinflammatory, neuroinfectious, and neurodegenerative disease. J Neurosci Res 1998, 51:423-430. 10.1002/(SICI)1097-4547(19980215)51:4<423::AID-JNR2>3.0.CO;2-E, 9514196.
143. Faraci FM, Lentz SR. Hyperhomocysteinemia, oxidative stress, and cerebral vascular dysfunction. Stroke 2004, 35:345-347. 10.1161/01.STR.0000115161.10646.67, 14757874.
144. Isingrini E, Desmidt T, Belzung C, Camus V. Endothelial dysfunction: A potential therapeutic target for geriatric depression and brain amyloid deposition in Alzheimer's disease?. Cur Opin Investig Drugs 2009, 10:46-55.
145. Bomboi F, Castello L, Cosentino F, Giubilei F, Orzi F, Volpe M. Alzheimer's disease and endothelial dysfunction. Neurol Sci 2010, 31:1-8. 10.1007/s10072-009-0151-6, 19838624.
146. Salmina AB, Inzhutova AI, Malinovskaya NA, Petrova MM. Endothelial dysfunction and repair in Alzheimer-type neurodegeneration: Neuronal and glial control. J Alzheimer Dis 2010, 22:17-36.
147. Sumpio BE, Riley JT, Dardik A. Cells in focus: endothelial cell. Int J Biochem Cell Biol 2002, 34:1508-1512. 10.1016/S1357-2725(02)00075-4, 12379270.
148. Moser KV, Stöckl P, Humpel C. Cholinergic neurons degenerate when exposed to conditioned medium of primary rat brain capillary endothelial cells: counteraction by NGF, MK-801 and inflammation. Exp Gerontol 2006, 41:609-618. 10.1016/j.exger.2006.03.018, 16701975.
149. Grammas P, Ottman T, Reimann-Phillip U, Larabee J, Weigel PH. Injured endothelial cells release neurotoxic thrombin. J Alzheimer Dis 2004, 6:275-281.
150. Bell RD, Winkler EA, Sagare AP, Singh I, LaRue B, Deane R, Zlokovic BV. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during aging. Neuron 2010, 68:321-323. 10.1016/j.neuron.2010.09.043, 21040834.
151. Akiyama H, Ikeda K, Kondo H, McGeer PL. Thrombin accumulation in patients with Alzheimer's disease. Neurosci Lett 1992, 146:152-154. 10.1016/0304-3940(92)90065-F, 1491781.
152. Mortimer JA, van Duijn CM, Chandra V, Fratiglioni L, Graves AB, Heyman A. Head trauma as a risk factor for Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol 1991, 20:S28-S35.
153. Nemetz PN, Leibson C, Naessens JM, Beard M, Kokmen E, Annegers JF, Kurland LT. Traumatic brain injury and time to onset of Alzheimer's disease: a population based study. Am J Epidemiol 1999, 149:32-40.
154. Nishino A, Suzuki M, Ohtani H, Motohashi O, Umezawa K, Nagura H, Yoshimoto T. Thrombin may contribute to the pathophysiology of central nervous system injury. J Neurotraum 1993, 10:167-179.
155. Sokolova E, Reiser G. Prothrombin/thrombin and the thrombin receptors PAR-1 and PAR-4 in the brain: localization, expression and participation in neurodegenerative diseases. Thromb Haemost 2008, 100:576-581.
156. Vaughan PL, Su J, Cotman CW, Cunningham D. Protease nexin-1, a potent thrombin inhibitor, is reduced around cerebral blood vessels in Alzheimer's disease. Neuroreport 1994, 5:2529-2533. 10.1097/00001756-199412000-00031, 7696596.
157. Maragoudakis ME, Tsopanoglou NE, Andriopoulou P. Mechanism of thrombin-induced angiogenesis. Biochem Soc Trans 2002, 30:173-177. 10.1042/BST0300173, 12023846.
158. Naldini A, Carney DH, Pucci A, Pasquali A, Carraro F. Thrombin regulates the expression of proangiogenic cytokines via proteolytic activation of protease-activated receptor-1. Gen Pharmacol 2000, 35:255-259.
159. Dupuy E, Habib A, Lebret M, Yang R, Levy-Toledano S, Tobelem G. Thrombin induces angiogenesis and vascular endothelial growth factor expression in human endothelial cells: possible relevance to HIF-1α. J Thromb Haemost 2003, 1:1096-1102. 10.1046/j.1538-7836.2003.00208.x, 12871382.
160. Tsopanoglou NE, Andriopoulou P, Maragoudakis ME. On the mechanism of thrombin-induced angiogenesis: involvement of alphavbeta3-integrin. Am J Physiol 2002, 283:C1501-C1510.
161. Smirnova, Zhang SX, Citron BA, Arnold PM, Festoff BW. Thrombin is an extracellular signal that activates intracellular death protease pathways inducing apoptosis in model motor neurons. J Neurobiol 1998, 36:64-80. 10.1002/(SICI)1097-4695(199807)36:1<64::AID-NEU6>3.0.CO;2-8, 9658339.
162. Turgeon VL, Milligan CE, Houenou LJ. Activation of the protease-activated thrombin receptor (PAR)-1 induces motoneuron degeneration in the developing avian embryo. J Neuropathol Exp 1999, 58:499-504.
163. Festoff BW, D'Andrea MR, Citron BA, Salcedo RM, Smirnova IV, Andrade-Gordon P. Motor neuron cell death in wobbler mutant mice follows overexpression of the G-protein coupled, protease-activated receptor for thrombin. Mol Med 2000, 6:410-429. 1949954, 10952021.
164. Reimann-Philipp U, Ovase R, Lapus M, Weigel PH, Grammas P. Mechanisms of cell death in primary cortical neurons and PC12 cells. J Neurosci Res 2001, 64:654-660. 10.1002/jnr.1119, 11398190.
165. Suo Z, Wu M, Citron BA, Palazzo RE, Festoff BW. Rapid tau aggregation and delayed hippocampal neuronal death induced by persistent thrombin signaling. J Biol Chem 2003, 278:37681-37689. 10.1074/jbc.M301406200, 12821672.
166. Mhatre M, Nguyen A, Pham T, Adesina A, Grammas P. Thrombin, a mediator of neurotoxicity and memory impairment. Neurobiol Aging 2004, 25:783-79. 10.1016/j.neurobiolaging.2003.07.007, 15165703.
167. Lee da Y, Park KW, Jin BK. Thrombin induces neurodegeneration and microglial activation in the cortex in vivo and in vitro: proteolytic and non-proteolytic actions. Biochem Biophys Res Commun 2006, 346:727-738. 10.1016/j.bbrc.2006.05.174, 16777064.
168. Luo W, Wang Y, Reiser G. Protease-activated receptors in the brain: receptor expression, activation, and functions in neurodegeneration. Brain Res Rev 2007, 56:331-345. 10.1016/j.brainresrev.2007.08.002, 17915333.
169. Park KW, Jin BK. Thrombin-induced oxidative stress contributes to the death of hippocampal neurons: role of neuronal NADPH oxidase. J Neurosci Res 2008, 86:1053-1063. 10.1002/jnr.21571, 18183616.
170. Rao HV, Thirumangalakudi L, Grammas P. Cyclin C and cyclin dependent kinases 1,2 and 3 in thrombin-induced neuronal cell cycle progression and apoptosis. Neurosci Lett 2009, 450:347-350. 10.1016/j.neulet.2008.12.018, 2734191, 19103257.
171. Huang CF, Li G, Ma R, Sun SG, Chen JG. Thrombin-induced microglial activation contributes to the degeneration of nigral dopaminergic neurons in vivo. Neurosci Bull 2008, 24:66-72. 10.1007/s12264-008-0066-x, 18369384.
172. Huang C, Ma R, Sun S, Wei G, Fang Y, Liu R, Li G. JAK2-STAT3 signaling pathway mediates thrombin-induced proinflammatory actions of microglia in vitro. J Neuroimmunol 2008, 204:118-125. 10.1016/j.jneuroim.2008.07.004, 18710787.
173. Choi MS, Kim YE, Lee WJ, Choi JW, Park GH, Kim SD, Jeon SJ, Go HS, Shin SM, Kim WK, Shin C, Ko KH. Activation of protease-activated receptor1 mediates induction of matrix metalloproteinase-9 by thrombin in rat primary astrocytes. Brain Res Bull 2008, 76:368-375. 10.1016/j.brainresbull.2008.02.031, 18502312.
174. Park JA, Choi KS, Kim SY, Kim KW. Coordinated interaction of the vascular and nervous systems: from molecule- to cell-based approaches. Biochem Biophys Res Commun 2003, 311:247-253. 10.1016/j.bbrc.2003.09.129, 14592405.
175. Benarroch E. Neurovascular unit dysfunction: A vascular component of Alzheimer's disease?. Neurology 2007, 68:1730-1732. 10.1212/01.wnl.0000264502.92649.ab, 17502556.
176. Lok J, Gupta P, Guo S, Kim WJ, Whalen MJ, van Leyen K, Lo EH. Cell-cell signaling in the neurovascular unit. Neurochem Res 2007, 32:2032-2045. 10.1007/s11064-007-9342-9, 17457674.
177. Guo S, Lo EH. Dysfunctional cell-cell signaling in the neurovascular unit as a paradigm for central nervous system disease. Stroke 2009, 40(suppl 1):S4-S7. 10.1161/STROKEAHA.108.534388, 19064781.
178. Zacchigna S, Lambrechts D, Carmeliet P. Neurovascular signaling defects in neurodegeneration. Nat Rev Neurosci 2008, 9:169-181. 10.1038/nrn2336, 18253131.
179. Zeevi N, Pachter J, McCullough LD, Wolfson L, Kuchel GA. The blood-brain barrier: geriatric relevance of a critical brain-body interface. J Am Geriatr Soc 2010, 58:1749-1757. 10.1111/j.1532-5415.2010.03011.x, 20863334.
180. Deane R, Wu Z, Zlokovic BV. RAGE (yin) versus LRP (yang) balance regulates Alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke 2004, 35:2628-2631. 10.1161/01.STR.0000143452.85382.d1, 15459432.
181. Bell RD, Zlokovic BV. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol 2009, 118:103-113. 10.1007/s00401-009-0522-3, 2853006, 19319544.
182. Bartha K, Dömötör E, Lanza F, Adam-Vizi V, Machovick R. Identification of thrombin receptors in rat brain capillary endothelial cells. J Cereb Blood Flow 2000, 20:175-182.
183. Igarashi K, Murai H, Asaka J. Proteolytic processing of amyloid beta protein precursor (APP) by thrombin. Biochem Biophys Res 1992, 185:1000-1004.
184. Ciallela JR, Figueiredo H, Smith-Swintosky V, McGillis JP. Thrombin induces surface and intracellular secretion of amyloid precursor protein from human endothelial cells. Thromb Haemost 1999, 81:630-637.